Troponins are proteins that are integral components of the contractile mechanism of muscle, including cardiac muscle. Cardiac troponins I and T can be detected in the blood of most people after puberty, at concentrations reflecting cardiac mass, sex and age.

Current laboratory assays are approximately 1000 times more sensitive than those used previously. They also have higher sensitivity than point-of-care assays.

The measurement of cardiac troponins is used primarily to assist in the diagnosis or exclusion of myocardial injury. Serial tests in acute coronary syndrome are guided by the Universal Definition of Myocardial Infarction.



Troponins are proteins that regulate muscle contraction.1 In the myocardium the subunits are cardiac troponin I (cTnI), cardiac troponin T (cTnT) and cardiac troponin C. All three are integral components of the contractile mechanism of cardiac muscle (see Fig. 1). They have separate genes, which differentiate them from skeletal muscle troponin.

Fig. 1 - Cardiac muscle

Ca2+ Calcium ions
Source: Adapted, with permission from Elsevier, from reference 1.

Immunoassays have been developed for both cTnI and cTnT and either of these troponins can be used in the investigation of possible myocardial injury or infarction. As cardiac troponins are specific for myocardial tissue, they have now replaced creatine kinase-MB for investigating possible myocardial injury.


Troponin assays

Early assays for cTnI and cTnT were relatively insensitive. Only high concentrations could be detected in the circulation. This led to the concept that troponin release from the myocardium only occurred after significant ischaemic damage. The detection of troponins in the blood became almost synonymous with acute coronary syndrome. However, newer assays are approximately 1000-fold more sensitive so they can detect troponins in people without ischaemia. Low concentrations can be detected in the circulation in healthy people throughout life, and almost all children from near puberty have detectable cTnI in their blood.2 Plasma concentrations are lower in females than males because of their smaller cardiac mass. Many causes of myocardial damage other than ischaemia are associated with troponin elevations in the circulation and high concentrations can occur in marathon runners (Box 1).3-6 The diagnosis or exclusion of acute coronary syndrome remains the most common and important reason for measuring troponins.

Box 1 - Examples of causes of elevated cardiac troponin3

Cardiac ischaemia
Acute coronary syndrome/Type 1 myocardial infarction
Heart failure
Type II myocardial infarction. Supply and demand mismatch e.g. hypotension including intraoperative, cardiac dysrhythmias and significant blood loss

Cardiac inflammatory and infiltrative diseases (various aetiologies)

Pulmonary embolism
Adult respiratory distress syndrome, respiratory failure
End-stage renal disease

Viruses – various, including COVID-19 Sepsis

Carbon monoxide poisoning
Drugs e.g. clozapine, chemotherapy4
Envenomation e.g. jellyfish and snake5,6

Blunt force trauma e.g. motor vehicle accident
Endurance sports

The half-life of cardiac troponins

The actual half-life of both cTnI and cTnT is short – approximately two hours in plasma.7 However, because of continued leaching of troponin from necrotic myocardium, the apparent half-life is of the order of 24 hours with cTnT slightly longer.8


What is measured

For technical reasons (namely the sample volume used) cTnI assays measure to lower concentrations than cTnT. However, in the diagnosis of myocardial infarction there is little difference between cTnT and cTnI. An exception is in patients undergoing haemodialysis, where cTnT is marginally superior in identifying those at risk of cardiac death.9 Whether a particular laboratory measures cTnI or cTnT will depend on the analytical equipment it has chosen. Only one company offers cTnT, whereas multiple platforms offer cTnI assays.

All troponin assays offered in major hospital and pathology laboratories in Australia are high-sensitivity assays. However, the concentrations measured by different assays are not interchangeable. The equipment manufacturers have not benchmarked their particular antibodies against each other and there has been no harmonisation of the immunoassays. This means that the reference intervals reported by different laboratories will vary.

Some small laboratories and geographically more remote locations are unable to support significant large instrumentation and rely on point-of-care testing for troponin. While these tests are generally robust, their limits of detection are higher. For example, the limit of detection for cTnI may be 20 nanogram/L compared with 2 nanogram/L for a high-sensitivity assay.10 For measuring cTnT using the point-of-care testing, the limit of detection is 100 nanogram/L versus 5 nanogram/L for a high-sensitivity assay.11 As significant myocardial injury can occur with troponin concentrations below the limits of detection, some cases of concern may be missed by point-of-care tests. High-sensitivity point-of-care assays are in development, but are not currently in use in Australia.


Troponins and acute myocardial infarction

The Fourth Universal Definition of Myocardial Infarction (Box 2) requires a rise and fall in troponin concentration with at least one result above the 99th percentile, and objective evidence of myocardial ischaemia.12 The most common form of acute coronary syndrome seen in the emergency department is type 1 myocardial infarction. This is caused by the rupture of an atheromatous plaque, thrombi formation and embolisation causing coronary artery obstruction and necrosis. Type 2 myocardial infarction occurs when oxygen delivery to the myocardium is inadequate.13 Other types of myocardial infarction are rare.

Box 2 - Fourth universal definition of myocardial injury and myocardial infarction12

Myocardial injury
Troponin concentration above the 99th percentile

Myocardial infarction (type 1)
A rise and fall in troponin concentration with at least one value above the 99th percentile
Symptoms of myocardial ischaemia
New ischaemic ECG changes
Development of pathological Q waves
Imaging evidence of loss of viable myocardium or new regional wall abnormality

The universal definition uses the 99th percentile of troponin concentrations in a healthy population. This is challenging as defining a healthy population is difficult. Detailed examination shows many apparently healthy people have significant sub-clinical cardiac disease. Depending on how carefully a population is chosen, the reported 99th percentile can vary markedly.14 In addition, both sex and age (increase with age) are important contributors to population data sets even in a carefully selected population.15 In Australia the 99th percentiles (depending on the assay used) are:

  • cTnI males 26 nanogram/L, females 16 nanogram/L
  • cTnT males 15.5 nanogram/L, females 9 nanogram/L.

The universal definition introduced the 99th percentile to assist the recognition of clinically important elevations of cardiac troponin. However, it is important to recognise that with the very small biological variation of both cTnT and cTnI in healthy individuals these concentrations may fall well below the 99th percentile. A pathologically significant troponin release can therefore occur and still be below the 99th percentile in some individuals.16


Interpretation of results

The single major use of troponin assays is for the diagnosis or exclusion of acute myocardial infarction in the emergency department. Only 5–10% of people who are assessed are ultimately proven to have a myocardial infarction.17 Troponin is therefore mainly used in the emergency department as a ‘rule-out’ test. A low troponin concentration at presentation with small changes over a period of 1–3 hours provides the best rule-out rates.18 Sex-specific cutpoints are recommended for use by both the Fourth Universal Definition of Myocardial Infarction and the current guidelines of the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand.19 Using these different cutpoints has increased the diagnosis of acute coronary syndrome in females.20

Particularly in the early days of troponin testing, cardiologists were concerned over the large numbers of patients referred with small increases in troponin unrelated to acute coronary syndrome or acute myocardial infarction. In attempting to reduce these ‘false positives’, the 99th percentile was introduced as a diagnostic criterion, making troponin a ‘rule-in’ test.21


In myocardial infarction there is an acute change in troponin concentration, however, patients may present days after their initial chest pain. Concentrations of cTnI may remain elevated for up to 4–5 days and cTnT up to 10 days, but two samples collected 2–3 hours apart may not be significantly different.

Troponin testing in general practice is not encouraged, as the troponin concentration alone does not rule out acute coronary syndrome.19 A definitive risk stratification (with more than just a single measurement) is required. There are exceptions to this in rural or remote settings, or in patients presenting several days after symptom onset.

Cardiac troponins are measured by immunoassays which are prone to interference by endogenous immunoglobulins. They may bind to either of the troponins, or to the exogenous antibodies that are used in the assays. These interferences can be either positive or negative. If a troponin result does not fit with a strong clinical impression, talk to the laboratory about possible investigations for interference.22


Other causes of cardiac troponin elevation

A raised troponin concentration may be a sign of myocardial injury rather than infarction. Figure 2 shows the relative time courses of the major cardiac causes of chest pain including acute myocardial infarction. The shared pathway for myocardial damage is either an absolute or relative insufficiency of oxygen availability to meet myocardial requirements (Box 1). Elevated cardiac troponins in pulmonary embolism and in heart failure identify high-risk patients, but do not significantly influence management. In all conditions investigated to date, an elevated cardiac troponin is associated with a poorer prognosis in adults23 and children.24

Fig. 2 - Troponin concentration–time curves26

Cardiac troponin T kinetics for ST-elevation myocardial infarction (STEMI) and non- ST-elevation myocardial infarction (NSTEMI) are typically biphasic compared to monophasic kinetics in myocarditis, pulmonary embolism (PE), and endurance sports. The concentration of high-sensitivity troponin T measured can vary markedly after a marathon run (shaded area) and can even supersede that of, for example, NSTEMI.

In chronic heart failure (CHF) troponin concentrations are persistent and often not elevated in the absence of an ischaemic episode.

hsTnt high-sensitivity cardiac troponin T concentration

Although some drugs used in chemotherapy are cardiotoxic,25 routine monitoring with troponins has not been adopted to identify patients at risk. In contrast, monitoring for the early transient cardiotoxicity which can occur when starting clozapine is more common.4

The finding of an unexpected elevated cardiac troponin requires explanation and clinical evaluation. For conditions in which the underlying cause is a mismatch of oxygen supply and demand, the expectation is a rise then fall in cardiac troponin (Fig. 2).26 Compare this with drug-related causes where the changes may occur over a different timeframe and depend on the mechanism of damage and clearance of the drug. In chronic conditions such as end-stage renal failure, the troponin concentrations remain elevated, but are reversed following renal transplantation.



The measurement of cardiac troponins has a role in the diagnosis of acute coronary syndrome. However, many other conditions cause a rise in troponin concentrations. The importance of troponin in the diagnosis of acute coronary syndrome should, to some extent, be de-emphasised, with more weight given to the clinical presentation of the individual patient. It is a synthesis of clinical examination, ECG assessment, cardiac troponin measurement and imaging that may be needed to make the diagnosis of acute coronary syndrome.27

Health professionals need to be aware of the factors that can affect the results of troponin assays. A raised troponin concentration may be a sign of myocardial injury rather than infarction.

Conflicts of interest: none declared

This article is peer-reviewed.


Australian Prescriber welcomes Feedback.



  1. Shave R, Baggish A, George K, Wood M, Scharhag J, Whyte G, et al. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol 2010;56:169-76.
  2. Koerbin G, Potter JM, Abhayaratna WP, Telford RD, Badrick T, Apple FS, et al. Longitudinal studies of cardiac troponin I in a large cohort of healthy children. Clin Chem 2012;58:1665-72.
  3. Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009;55:2098-112.
  4. Hopper I. Cardiac effects of non-cardiac drugs. Aust Prescr 2011;34:52-4.
  5. Allen GE, Brown SG, Buckley NA, O’Leary MA, Page CB, Currie BJ, et al.; ASP Investigators. Clinical effects and antivenom dosing in brown snake (Pseudonaja spp.) envenoming--Australian snakebite project (ASP-14). PLoS One 2012;7:e53188.
  6. Isbister GK. Managing injuries by venomous sea creatures in Australia. Aust Prescr 2007;30:117-21.
  7. Jaffe AS, Landt Y, Parvin CA, Abendschein DR, Geltman EM, Ladenson JH. Comparative sensitivity of cardiac troponin I and lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction. Clin Chem 1996;42:1770-6.
  8. Apple FS, Sharkey SW, Falahati A, Murakami M, Mitha N, Christensen D. Assessment of left ventricular function using serum cardiac troponin I measurements following myocardial infarction. Clin Chim Acta 1998;272:59-67.
  9. Hickman PE, McGill D, Potter JM, Koerbin G, Apple FS, Talaulikar G. Multiple biomarkers including cardiac troponins T and I measured by high-sensitivity assays, as predictors of long-term mortality in patients with chronic renal failure who underwent dialysis. Am J Cardiol 2015;115:1601-6.
  10. Australian Point of Care Practitioners’ Network. Abbott i-STAT Troponin I Method and Sample Collection IECTnI.1.v2 2.11.15. [cited 2022 Mar 1]
  11. Australian Point of Care Practitioners’ Network. Roche cobas h 232 Troponin T method and sample collection IECTnT.1.v1 19.1.12. [cited 2022 Mar 1]
  12. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/ World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction. J Am Coll Cardiol 2018;72:2231-64.
  13. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med 2013;126:789-97.
  14. Collinson PO, Heung YM, Gaze D, Boa F, Senior R, Christenson R, et al. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin Chem 2012;58:219-25.
  15. Hickman PE, Abhayaratna WP, Potter JM, Koerbin G. Age-related differences in hs-cTnI concentration in healthy adults. Clin Biochem 2019;69:26-9.
  16. Cullen L, Mueller C, Parsonage WA, Wildi K, Greenslade JH, Twerenbold R, et al. Validation of high-sensitivity troponin I in a 2-hour diagnostic strategy to assess 30-day outcomes in emergency department patients with possible acute coronary syndrome. J Am Coll Cardiol 2013;62:1242-9.
  17. Westwood ME, Armstrong N, Worthy G, Fayter D, Ramaekers BL, Grimm S, et al. Optimizing the use of high-sensitivity troponin assays for the early rule-out of myocardial infarction in patients presenting with chest pain: a systematic review. Clin Chem 2021;67:237-44.
  18. Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA, et al.; NHFA/CSANZ ACS Guideline 2016 Executive Working Group. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ 2016;25:895-951. [Erratum in: Heart Lung Circ 2017;26:1117]
  19. Lee KK, Ferry AV, Anand A, Strachan FE, Chapman AR, Kimenai DM, et al. Sex-specific thresholds of high-sensitivity troponin in patients with suspected acute coronary syndrome. J Am Coll Cardiol 2019;74:2032-43.
  20. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al. It’s time for a change to a troponin standard. Circulation 2000;102:1216-20.
  21. Ward G, Simpson A, Boscato L, Hickman PE. The investigation of interferences in immunoassay. Clin Biochem 2017;50:1306-11.
  22. Crewdson K, Thompson J, Thomas M. Cardiac troponin T is associated with mortality in patients admitted to critical care in a UK major trauma centre: a retrospective database analysis. J Intensive Care Soc 2019;20:132-7.
  23. Braun CK, Schaffer A, Weber B, Huber-Lang M, Kalbitz M, Preßmar J. The prognostic value of troponin in pediatric polytrauma. Front Pediatr 2019;7:477.
  24. Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, et al. Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc 2020;21;9:e014708.
  25. Sedeghat-Hamedani F, Katus HA, Meder B. Cardiac biomarker changes after endurance sports. Am Coll Cardiol 2016 Apr 14. [cited 2022 Mar 1]
  26. Hickman PE, Lindahl B, Cullen L, Koerbin G, Tate J, Potter JM. Decision limits and the reporting of cardiac troponin: meeting the needs of both the cardiologist and the ED physician. Crit Rev Clin Lab Sci 2015;52:28-44.

Julia M Potter

Emeritus professor, Australian National University Medical School, Canberra

Hon visiting medical officer, Canberra Hospital

Peter E Hickman

Associate professor, Australian National University Medical School, Canberra

Visiting medical officer, Canberra Hospital

Louise Cullen

Senior staff specialist, Emergency and Trauma Centre, Royal Brisbane and Women’s Hospital